FDA Posts ICH Q4B Analytical Guidances - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Posts ICH Q4B Analytical Guidances


ePT--the Electronic Newsletter of Pharmaceutical Technology

The US Food and Drug Administration (Rockville, MD, www.fda.gov) has published a draft guidance, Q4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria (RAAPAC), available online at http://www.fda.gov/cder/guidance/7386dft.htm. The guidance describes the  International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH, www.ich.org) Q4B draft standard (as revised in June), outlining the procedure for "acceptance by regulatory authorities of pharmacopoeial" standards for APAC (analytical procedures and/or acceptance criteria).  (ICH's  Q4 activities focus on harmonizing the requirements of the world's pharmacopoeias.)

At the same time, FDA published the first specific draft guidance under the RAAPAC procedure, Annex 1:  Residue on Ignition/Sulphated Ash General Chapter Analytical Procedures and/or Acceptance Criteria (APAC) (http://www.fda.gov/cder/guidance/7387dft.htm).

The guidance describes the reconciliation (via specification of sample size and a caveat on test-furnace calibration) of US Pharmacopeia, European Pharmacopoeia, and Japanese Pharmacopoeia testing procedures for residual ash, an index of the inorganic impurities in an organic sample.

The eight-page guidance and four-page annex were posted jointly by the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here